Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

This is study is to evaluate the safety and efficacy of cosibelimab in special populations with advanced cutaneous squamous cell carcinoma (CSCC). The name of the drug involved in this research study is: -cosibelimab (a type of an anti-PD-L1 antibody)

Trial Details

NCT ID
NCT07426484
Phase
PHASE4
Sponsor
Dana-Farber Cancer Institute
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Cosibelimab
  • Prednisone
  • Sirolimus
  • Everolimus
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • COHORT A: Participant must have a history of kidney transplant (at least 6 months prior to enrollment). (A history of more than one kidney transpla…
  • COHORT B: Participant must have a diagnosis of a hematologic malignancy, including chronic myeloproliferative neoplasm (CMN) or an indolent non-Hod…
  • Examples of indolent non-Hodgkin's lymphomas (NHL), including but not limited to:
  • Chronic lymphocytic leukemia (CLL)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →